1.82 USD
-0.04 (-2.41%)
1.8 USD
-0.02 (-1.1%)
Taking everything into account, CDXS scores 2 out of 10 in our fundamental rating. CDXS was compared to 57 industry peers in the Life Sciences Tools & Services industry. CDXS has a bad profitability rating. Also its financial health evaluation is rather negative. CDXS is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CDXS has reported negative net income.
In the past year CDXS has reported a negative cash flow from operations.
In the past 5 years CDXS always reported negative net income.
CDXS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CDXS has a Return On Assets of -51.59%. This is amonst the worse of the industry: CDXS underperforms 82.46% of its industry peers.
CDXS's Return On Equity of -165.92% is on the low side compared to the rest of the industry. CDXS is outperformed by 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.59% | ||
| ROE | -165.92% | ||
| ROIC | N/A |
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDXS has a Gross Margin of 79.31%. This is amongst the best in the industry. CDXS outperforms 98.25% of its industry peers.
In the last couple of years the Gross Margin of CDXS has remained more or less at the same level.
CDXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
2. Health
2.1 Basic Checks
CDXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDXS has been increased compared to 1 year ago.
Compared to 5 years ago, CDXS has more shares outstanding
The debt/assets ratio for CDXS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.41, we must say that CDXS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.41, CDXS is doing worse than 87.72% of the companies in the same industry.
CDXS has a Debt/Equity ratio of 1.03. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CDXS (1.03) is worse than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.41 |
ROIC/WACCN/A
WACC11.15%
2.3 Liquidity
CDXS has a Current Ratio of 4.12. This indicates that CDXS is financially healthy and has no problem in meeting its short term obligations.
CDXS has a better Current ratio (4.12) than 66.67% of its industry peers.
CDXS has a Quick Ratio of 4.02. This indicates that CDXS is financially healthy and has no problem in meeting its short term obligations.
CDXS's Quick ratio of 4.02 is fine compared to the rest of the industry. CDXS outperforms 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 4.02 |
3. Growth
3.1 Past
CDXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.64%, which is quite good.
CDXS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.87%.
CDXS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.83% yearly.
EPS 1Y (TTM)12.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
Revenue 1Y (TTM)-17.87%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%-32.98%
3.2 Future
Based on estimates for the next years, CDXS will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.71% on average per year.
The Revenue is expected to grow by 19.17% on average over the next years. This is quite good.
EPS Next Y25.65%
EPS Next 2Y24.37%
EPS Next 3Y21.3%
EPS Next 5Y12.71%
Revenue Next Year3.05%
Revenue Next 2Y4.13%
Revenue Next 3Y13.34%
Revenue Next 5Y19.17%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CDXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CDXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CDXS's earnings are expected to grow with 21.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.37%
EPS Next 3Y21.3%
5. Dividend
5.1 Amount
No dividends for CDXS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.82
-0.04 (-2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners74.43%
Inst Owner Change-7.07%
Ins Owners2.46%
Ins Owner Change7.79%
Market Cap164.38M
Revenue(TTM)52.93M
Net Income(TTM)-63.95M
Analysts81.54
Price Target6.71 (268.68%)
Short Float %5.59%
Short Ratio5.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.18%
Min EPS beat(2)-45.17%
Max EPS beat(2)16.81%
EPS beat(4)1
Avg EPS beat(4)-70.83%
Min EPS beat(4)-251.59%
Max EPS beat(4)16.81%
EPS beat(8)3
Avg EPS beat(8)-35.92%
EPS beat(12)5
Avg EPS beat(12)-23.74%
EPS beat(16)9
Avg EPS beat(16)-8.31%
Revenue beat(2)1
Avg Revenue beat(2)-23.96%
Min Revenue beat(2)-54.44%
Max Revenue beat(2)6.53%
Revenue beat(4)1
Avg Revenue beat(4)-23.66%
Min Revenue beat(4)-54.44%
Max Revenue beat(4)6.53%
Revenue beat(8)4
Avg Revenue beat(8)-3.25%
Revenue beat(12)5
Avg Revenue beat(12)-3.57%
Revenue beat(16)8
Avg Revenue beat(16)-0.26%
PT rev (1m)-1.74%
PT rev (3m)-7.06%
EPS NQ rev (1m)48.42%
EPS NQ rev (3m)61.32%
EPS NY rev (1m)0.17%
EPS NY rev (3m)3.33%
Revenue NQ rev (1m)33.24%
Revenue NQ rev (3m)47.5%
Revenue NY rev (1m)2.45%
Revenue NY rev (3m)2.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.26 | ||
| P/tB | 4.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.59
BVpS0.43
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.59% | ||
| ROE | -165.92% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.32% | ||
| FCFM | N/A |
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
F-Score3
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 209.25% | ||
| Cap/Sales | 10.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 4.02 | ||
| Altman-Z | -6.41 |
F-Score3
WACC11.15%
ROIC/WACCN/A
Cap/Depr(3y)106.81%
Cap/Depr(5y)185.7%
Cap/Sales(3y)6.52%
Cap/Sales(5y)7.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
EPS Next Y25.65%
EPS Next 2Y24.37%
EPS Next 3Y21.3%
EPS Next 5Y12.71%
Revenue 1Y (TTM)-17.87%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%-32.98%
Revenue Next Year3.05%
Revenue Next 2Y4.13%
Revenue Next 3Y13.34%
Revenue Next 5Y19.17%
EBIT growth 1Y-17.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.2%
EBIT Next 3Y12.55%
EBIT Next 5Y12.02%
FCF growth 1Y-48.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.46%
OCF growth 3YN/A
OCF growth 5YN/A
CODEXIS INC / CDXS FAQ
Can you provide the ChartMill fundamental rating for CODEXIS INC?
ChartMill assigns a fundamental rating of 2 / 10 to CDXS.
What is the valuation status of CODEXIS INC (CDXS) stock?
ChartMill assigns a valuation rating of 1 / 10 to CODEXIS INC (CDXS). This can be considered as Overvalued.
Can you provide the profitability details for CODEXIS INC?
CODEXIS INC (CDXS) has a profitability rating of 1 / 10.
How financially healthy is CODEXIS INC?
The financial health rating of CODEXIS INC (CDXS) is 3 / 10.